Welcome to our dedicated page for Belite Bio SEC filings (Ticker: BLTE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Belite Bio, Inc (NASDAQ: BLTE) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a foreign private issuer, including Form 6‑K current reports and shelf registration materials. These documents show how Belite Bio communicates key developments around its clinical programs, financings, and regulatory interactions for its lead candidate, Tinlarebant.
Belite Bio uses Form 6‑K to furnish press releases on topics such as quarterly financial results and corporate updates, completion of enrollment in pivotal trials like the global Phase 3 PHOENIX study in geographic atrophy, and progress in the Phase 3 DRAGON program in Stargardt disease type 1 (STGD1). Other 6‑K filings describe securities purchase agreements for registered direct offerings and private placements, including details on American Depositary Shares, warrants, and registration rights agreements.
Through its filings, the company also references its shelf registration statement on Form F‑3, which supports offerings of American Depositary Shares used to fund clinical development, regulatory milestones, and commercialization preparation. While Belite Bio’s filings do not include U.S. domestic forms such as 10‑K or 10‑Q, they serve a similar role in updating investors on business progress, clinical trial status, and capital structure.
On Stock Titan, users can review Belite Bio’s SEC submissions in one place and use AI-powered summaries to interpret complex financing terms, understand the context of clinical and regulatory announcements, and see how new capital raises relate to ongoing trials in STGD1 and geographic atrophy. Filings related to equity offerings, warrants, and registration rights can help readers follow potential dilution, capital availability, and the company’s strategy for funding late-stage drug development.
Belite Bio, Inc furnished a Form 6-K to provide investors with a press release titled “Belite Bio Reports Third Quarter 2025 Financial Results and Provides a Corporate Update.” The press release is attached as Exhibit 99.1 and incorporated by reference, meaning its contents are formally included in Belite Bio’s effective Securities Act registration statements from the filing date unless later superseded.
Belite Bio, Inc. (BLTE) Form 144 shows an insider sale notice for 96,950 American Depositary Shares (ADS), each representing one ordinary share, scheduled approximately for 09/18/2025 through J.P. Morgan Securities LLC. The filing reports an aggregate market value of $7,077,350 based on the shares to be sold, against 32,833,402 shares outstanding. The ADS were acquired on 12/31/2021 via an employee stock option exercise and were paid for in cash. The filer, identified as Yu‑Hsin Lin (c/o Belite Bio), previously sold small blocks of ADS on 08/07/2025 (269 ADS, $19,906) and 08/12/2025 (700 ADS, $51,856).
The filer attests they are not aware of any undisclosed material adverse information and the notice includes the usual certification language required by Rule 144.
Belite Bio, Inc. entered into securities purchase agreements for a private investment in public equity (PIPE), selling 1,953,124 ordinary shares and issuing Warrants to purchase 1,953,124 ordinary shares. The securities are priced at
The PIPE is expected to generate gross proceeds of approximately
Form 144 filing for Belite Bio, Inc. (BLTE) reports a proposed sale of 30,000 American Depositary Shares (each representing one ordinary share) through J.P. Morgan Securities LLC on NASDAQ with an aggregate market value of $1,902,600 and an approximate sale date of 08/21/2025. The filer acquired the 30,000 ADS on 03/07/2025 by exercising stock options and paid cash on that date. The filer states there were no securities sold in the past three months attributable to the same person, and the notice includes the standard Rule 144 representation about lack of undisclosed material information.
Belite Bio (Nasdaq: BLTE) filed a 424B5 to raise capital via a direct, best-efforts placement of 230,770 ADSs (1 ADS = 1 ordinary share) at $65.00 each, bundled one-for-one with five-year warrants exercisable at the same price. Gross proceeds total $15.0 million; the placement-agent fee is 6.5% ($0.975 m), leaving $14.0 m before other expenses. Proceeds are earmarked for working capital and general corporate purposes.
Post-offering share count rises to 32.83 m (33.06 m fully diluted). Warrants are immediately exercisable, unlisted, and capped at 9.99% beneficial ownership. Company lock-ups: 30 days (issuer) and 60 days (insiders & ≥5% holder). Closing is expected on 8 Aug 2025; Titan Partners Group acts as exclusive placement agent.
Risks disclosed include continued cash burn, reliance on lead drug Tinlarebant, potential PRC regulatory exposure despite limited China operations, likely PFIC status, dilution (immediate book-value drop of $59.75/ADS) and controlled-company governance exemptions. Last BLTE close (6 Aug 2025) was $67.99, implying a modest 4.4% discount. No change to Nasdaq listing of ADSs; warrants will not be listed.
FAQ
What is the current stock price of Belite Bio (BLTE)?
What is the market cap of Belite Bio (BLTE)?
